Revolutionizing Obesity Treatment | Metsera
We are a clinical-stage biotechnology company focused on engineering, developing, manufacturing, and ultimately commercializing a new generation of potent, ultra-long acting, …
Metsera Announces Positive Topline Phase 2a Clinical Data for its …
Jan 7, 2025 · Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad …
Metsera, Maze secure combined $415 million in IPOs
3 days ago · Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma Dive …
Metsera Touts ‘Powerful’ Weight Loss Results—Again
Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 …
Metsera reveals data supporting long-acting obesity shot
Jan 7, 2025 · Privately-held biotechnology startup Metsera said Tuesday a long-acting GLP-1 shot it’s developing helped people who are overweight or have obesity lose more weight than …
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 · Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the …
About Metsera: Leaders in Obesity Innovation
Learn about Metsera: a team of experts dedicated to reducing the burden of obesity through cutting-edge NuSH therapies built on 20+ years of peptide engineering research.
Arch-backed obesity biotech launches with $290M - Fierce Biotech
Apr 18, 2024 · Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. “It's …
Metsera Launches to Lead the Next Generation of Medicines for …
NEW YORK, April 18, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and …
Metsera Reports Highly Competitive Results from Ongoing Trial …
NEW YORK, September 24, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and …